Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Encysive Pharmaceuticals has said that Thelin 100mg tablets have been launched in the Netherlands for the treatment of pulmonary arterial hypertension.
Subscribe to our email newsletter
The company received European Union marketing authorization for Thelin in August 2006. Thelin is the first selective endothelin A receptor antagonist and the first once-daily oral treatment available for patients with pulmonary arterial hypertension (PAH).
Endothelin receptor antagonists may prove to be effective in the treatment of a variety of diseases where the regulation of vascular constriction is important. Highly selective endothelin A receptor antagonism has been shown to increase blood flow and reverse vasoconstriction in human clinical pharmacology studies.
“As a once-daily oral therapy, Thelin may provide PAH patients with effective symptom management in a convenient, non-invasive route of administration,” said Anco Boonstra, pulmonologist, Vrije Universiteit Medical Center, Amsterdam.